Adma Biologics Stock Investor Sentiment

ADMA Stock  USD 21.83  0.01  0.05%   
About 60% of ADMA Biologics' investor base is looking to short. The analysis of the overall investor sentiment regarding ADMA Biologics suggests that many traders are alarmed. The current market sentiment, together with ADMA Biologics' historical and current headlines, can help investors time the market. In addition, many technical investors use ADMA Biologics stock news signals to limit their universe of possible portfolio assets.
  

ADMA Biologics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards ADMA Biologics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over three months ago at finance.yahoo.com         
Adma Biologics Suffers a Larger Drop Than the General Market Key Insights
Yahoo News
over three months ago at zacks.com         
Adma Biologics Suffers a Larger Drop Than the General Market Key Insights
zacks News
over three months ago at news.google.com         
ADMA Biologics A Compelling GARP Stock For Biotech Investors - Seeking Alpha
Google News at Macroaxis
over three months ago at www.macroaxis.com         
Acquisition by Tade Brad L. of 72400 shares of ADMA Biologics subject to Rule 16b-3
Macroaxis News
over three months ago at zacks.com         
Is Aclaris Therapeutics Outperforming Other Medical Stocks This Year?
zacks News
over three months ago at finance.yahoo.com         
Recent Price Trend in Adma Biologics is Your Friend, Heres Why
Yahoo News
over three months ago at zacks.com         
Recent Price Trend in Adma Biologics is Your Friend, Heres Why
zacks News
over three months ago at zacks.com         
Disposition of 50000 shares by Brad Tade of ADMA Biologics subject to Rule 16b-3
zacks News
over three months ago at finance.yahoo.com         
Adma Biologics Stock Moves -1.31 percent What You Should Know
Yahoo News
over three months ago at simplywall.st         
ADMA Biologics, Inc. Stock Rockets 25 percent As Investors Are Less Pessimistic Than Expected
Simply Wall St News at Macroaxis
over three months ago at zacks.com         
Adma Biologics Stock Moves -1.31 percent What You Should Know
zacks News
over three months ago at benzinga.com         
Jim Cramer Recommends Not Selling Vertiv, Says Buy This Social Media Stock Hand Over Fist
benzinga news
over three months ago at finance.yahoo.com         
Whats in Store for ADMA Biologics in Q2 Earnings?
Yahoo News
over three months ago at finance.yahoo.com         
Adma Biologics Declines More Than Market Some Information for Investors
Yahoo News
over three months ago at zacks.com         
Adma Biologics Declines More Than Market Some Information for Investors
zacks News
Far too much social signal, news, headlines, and media speculation about ADMA Biologics that are available to investors today. That information is available publicly through ADMA media outlets and privately through word of mouth or via ADMA internal channels. However, regardless of the origin, that massive amount of ADMA data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of ADMA Biologics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of ADMA Biologics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to ADMA Biologics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive ADMA Biologics alpha.

ADMA Biologics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 24150 shares by Kestenberg-messina Kaitlin M. of ADMA Biologics at 16.8965 subject to Rule 16b-3
09/27/2024
2
Acquisition by Adam Grossman of 870950 shares of ADMA Biologics at 5.4 subject to Rule 16b-3
10/04/2024
3
Is First Trust Small Cap Core AlphaDEX ETF a Strong ETF Right Now
10/22/2024
4
Adma Biologics Soars 18.8 percent Is Further Upside Left in the Stock
11/04/2024
5
ADMA Biologics Inc Q3 2024 Earnings Call Highlights Record Revenue and Net Income Surge
11/08/2024
6
Statutory Profit Doesnt Reflect How Good ADMA Biologics Earnings Are
11/15/2024
7
ADMA Biologics, Inc. Is Being Investigated For Defrauding The Public And Affected Investors Are Urged To Contact The Schall Law Firm
11/18/2024
8
The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ADMA Biologics Inc For Securities Law Violations
11/19/2024
9
ADMA Biologics announces board changes and new audit chair
11/21/2024
10
ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Invited To Contact The Schall Law Firm
11/22/2024
11
The Schall Law Firm Wants Shareholders With Losses To Join An Inquiry Into ADMA Biologics Inc For Securities Related Infractions
11/25/2024
12
Biotech Leader ADMA Hits New Buy Point After Recovering From Surprise Plunge
11/26/2024

Complementary Tools for ADMA Stock analysis

When running ADMA Biologics' price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.